HISTOACRYL® Used for Embolization of Thoracoabdominal Artery Bleeding (NCT07753005) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
HISTOACRYL® Used for Embolization of Thoracoabdominal Artery Bleeding
Japan176 participantsStarted 2026-09-30
Plain-language summary
This observational study will collect information from adult patients in Japan who are treated with Histoacryl® to stop bleeding from arteries in the chest or abdomen, in order to better understand how well the treatment works and how safe it is during routine medical care.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Active thoracoabdominal arterial bleeding diagnosed by endoscopy, catheter angiography, or computed tomography angiography (CTA).
* Planned embolization treatment using Histoacryl® as the sole embolic agent for the target lesion.
* No endoleak following thoracic endovascular aortic repair (TEVAR) or endovascular abdominal aortic repair (EVAR).
* Patients with malignant tumors must have an expected survival of at least 1 month.
* Written informed consent obtained from the patient or a legally authorized representative.
Exclusion Criteria:
* Previous embolization in the target vascular territory.
* Known allergy or hypersensitivity to n-butyl cyanoacrylate (NBCA), Lipiodol®, or related treatment components.
* Use of adjunctive embolic agents in the same target location.
* Planned surgical treatment after embolization as part of a predefined two-step treatment strategy.
* Severe septicemia.
* Participation in another clinical trial.
* Target vessels unsuitable for safe Histoacryl® injection.
* Empiric embolization without identification of a target bleeding location.
* Pregnancy, with the exception of patients treated for postpartum hemorrhage.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Clinical Success at 1 Month After Histoacryl® Embolization
Timeframe: 30 ± 10 days after index embolization procedure